CNCE stock slides on 10M common stock offering (NASDAQ:CNCE)
seekingalpha.com
finance
2022-06-01 10:31:24

Daniel Grizelj/DigitalVision via Getty Images Concert Pharmaceuticals (NASDAQ:CNCE), a clinical-stage biotech focused on autoimmune diseases, has lost ~15% in the pre-market Wednesday after the company announced an underwritten public offering of 10M shares of its common stock. A decision to grant a 30-day option for underwriters is also under consideration allowing them to purchase up to an additional 1.5M of the shares of the common stock sold in the offering at the on the same terms and conditions.
